"GEFISTERIS 250: Optimal Gefitinib 250mg Cancer Treatment"

GEFISTERIS 250 

 Gefitinib (250mg)

Gefitinib (250mg)

Overview of GEFISTERIS 250

GEFISTERIS 250, with the active compound Gefitinib in a 250mg dose, is a targeted therapy medication used in the treatment of non-small cell lung cancer (NSCLC). It belongs to the class of drugs known as tyrosine kinase inhibitors, specifically targeting the epidermal growth factor receptor (EGFR) pathway, which is often overactive in lung cancer cells.

Mechanism of Action

• EGFR Inhibition: GEFISTERIS 250 works by blocking the activity of the EGFR tyrosine kinase, an enzyme that promotes tumor cell growth.
• Selective Action: It selectively inhibits the growth of cancer cells with EGFR mutations, sparing normal cells.
• Tumor Growth Reduction: By inhibiting EGFR, it prevents the cancer cells from growing and dividing.

Key Benefits

• Targeted Therapy: Offers a more focused approach to cancer treatment with potentially fewer side effects.
• Improved Survival Rates: Has been shown to improve the survival and quality of life in patients with EGFR-mutated NSCLC.
• Oral Administration: Convenient oral tablet form allows for home treatment.

Usage Guidelines

• Treatment Regimen: Usually prescribed as one 250mg tablet per day.
• Continuous Monitoring: Regular monitoring for side effects and response to therapy is essential.

Side Effects and Management

• Common Side Effects: Include skin rash, diarrhea, and liver function test abnormalities.
• Side Effect Management: Most side effects are manageable with supportive care and dose adjustments if necessary.

Comparative Efficacy

• Clinical trials have demonstrated that GEFISTERIS 250 is effective in patients with specific types of EGFR mutations, often leading to better outcomes compared to traditional chemotherapy.

Patient Experience

• Quality of Life Improvement: Many patients report a significant improvement in symptoms and overall quality of life.
• Treatment Compliance: The ease of taking a once-daily pill and manageable side effect profile contributes to high treatment compliance.

In summary, GEFISTERIS 250 is a cornerstone in the management of EGFR-mutated NSCLC, offering targeted, effective treatment with the convenience of oral administration. Its role in enhancing patient outcomes underscores the importance of personalized medicine in oncology.  A team of highly skilled professionals in the pharmaceutical field established Steris Healthcare Pvt Ltd in February 2018. Sterispharma is a certified pharmaceutical company by WHO, GMP, and ISO, situated in Navi Mumbai. It is dedicated to delivering high-quality medications at competitive prices to customers across India, adhering to WHO's stringent standards. Through Steris's online pharmacy, customers can conveniently purchase medicines and receive home delivery. Our primary objective at Steris is to offer a comprehensive range of healthcare products to fulfill the diverse requirements of the healthcare industry. Steris is committed to meeting the healthcare sector's demands, whether it's specialized treatments, medications for rare diseases, or essential pharmaceuticals. The range of Steris healthcare products caters to various medical needs, including Cardiology, Asthma, Respiratory, Nasal, Diabetes, Endocrinology, Gastrology, Orthopedics, Anti-infective/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental, and Dermatology.  For further information:  EMAIL:  info@sterispharma.com  / contact@sterispharma.com     CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668   

  BUY NOW